✨ Free AI Report
Shanghai Allist Pharmaceuticals Co., Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Shanghai Allist Pharmaceuticals Co., Ltd.
Company Research

Shanghai Allist Pharmaceuticals Co., Ltd.: Business Overview, Financials & Competitive Analysis

Shanghai Allist Pharmaceuticals is an innovation-oriented Chinese pharmaceutical company specializing in tumor-targeted drugs and therapies. Founded in 2004 and listed on the Shanghai Stock Exchange in December 2020, ...

Analyst-debate audio for Shanghai Allist Pharmaceuticals Co., Ltd.

AskCyborg analysts argue the bull and bear cases for Shanghai Allist Pharmaceuticals Co., Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Well-positioned oncology specialist with differentiated lung cancer franchise and expanding pipeline accessing high-value...

Read the full analyst-debate transcript →
Industry Oncology Pharmaceuticals / Tumor-Targeted Drug Development
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Shanghai Allist Pharmaceuticals Co., Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Shanghai Allist Pharmaceuticals Co., Ltd. Overview

Pro stress-test →

Shanghai Allist Pharmaceuticals is an innovation-oriented Chinese pharmaceutical company specializing in tumor-targeted drugs and therapies. Founded in 2004 and listed on the Shanghai Stock Exchange in December 2020, the company focuses on developing first-in-class and best-in-class oncology medicines addressing unmet global clinical needs.

Strategic Profile

Pro stress-test →

Allist has established itself as a specialized oncology player with core competencies in lung cancer therapeutics. The company leverages both proprietary drug development capabilities and strategic in-licensing agreements to expand its pipeline, positioning itself to compete in the global pharmaceutical market while maintaining strong domestic commercialization channels.

Competitive Landscape

Pro stress-test →

Allist competes within the oncology space against both domestic Chinese pharmaceutical companies and international players. Its primary competitive advantage rests in the lung cancer market where Furmonertinib has established a strong foothold. Major comparators include international standards like Osimertinib (AstraZeneca) and Afatinib, though Furmonertinib's clinical profile demonstrates superior mPFS in certain EGFR mutation subtypes.

Industry Context

Shanghai Allist Pharmaceuticals Co., Ltd. operates in Oncology Pharmaceuticals / Tumor-Targeted Drug Development.

Key facts

Founded: 2004 · Headquarters: Shanghai, China · Employees: 1,823 · Market cap: 47.4B CNY

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Shanghai Allist Pharmaceuticals Co., Ltd..

  • Furmonertinib has achieved remarkable commercial success with strong sales performance since launch and multiple indication expansion potential
  • Recent out-licensing deal with Jacobio Pharma (August 2024) brings KRAS G12C and SHP2 inhibitors to expand oncology portfolio beyond EGFR-targeted therapies
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • July 2025Furmonertinib second-line NSCLC indication included in priority review process with reported 16-month mPFS in 240mg dose group
  • August 2024In-licensed KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 from Jacobio Pharma for China rights
  • +1 moreTrack every material event for Shanghai Allist Pharmaceuticals Co., Ltd. as it happens. Explore monitoring →
Get alerted when Shanghai Allist Pharmaceuticals Co., Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

OsimertinibLeading EGFR-TKI for NSCLC→AfatinibEGFR-TKI for advanced lung cancer→GlecirasibKRAS G12C inhibitor for lung cancer→

Compare Shanghai Allist Pharmaceuticals Co., Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Shanghai Allist Pharmaceuticals Co., Ltd. operates in Oncology Pharmaceuticals / Tumor-Targeted Drug Development. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Pharmaceuticals / Tumor-Targeted Drug Development research →
NEW · MCP server

Ask your AI assistant about Shanghai Allist Pharmaceuticals Co., Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Shanghai Allist Pharmaceuticals Co., Ltd. and its top competitor on Cyborg Score”
“What did Shanghai Allist Pharmaceuticals Co., Ltd. do this quarter?”
“Is Shanghai Allist Pharmaceuticals Co., Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Shanghai Allist Pharmaceuticals Co., Ltd. do?+
Shanghai Allist Pharmaceuticals is an innovation-oriented Chinese pharmaceutical company specializing in tumor-targeted drugs and therapies. Founded in 2004 and listed on the Shanghai Stock Exchange in December 2020, ...
What is Shanghai Allist Pharmaceuticals Co., Ltd.'s Cyborg Score?+
Shanghai Allist Pharmaceuticals Co., Ltd. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Shanghai Allist Pharmaceuticals Co., Ltd.'s main competitors?+
Named competitors include Osimertinib, Afatinib, Glecirasib. The full competitive landscape is in the AskCyborg report.
How can I get the full Shanghai Allist Pharmaceuticals Co., Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Shanghai Allist Pharmaceuticals Co., Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Shanghai Allist Pharmaceuticals Co., Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.